Search results
Showing 241 to 255 of 261 results for carcinoma
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
This guidance has been updated and replaced by NICE technology appraisal guidance TA802.
Discontinued Reference number: GID-TA10202
In development Reference number: GID-TA11556 Expected publication date: TBC
This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
This guidance has been updated and replaced by NICE technology appraisal guidance 692.
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
This guidance has been updated and replaced by NICE technology appraisal guidance 736.
In development Reference number: GID-TA11433 Expected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.
Endoscopic full thickness removal of non-lifting colonic polyps (IPG580)
Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.
View recommendations for IPG580Show all sections
In development Reference number: GID-TA11582 Expected publication date: TBC
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.